MedTrace Logo

Cognitive and Balance Dual Task Training for People With Schizophrenia

NCT05341804 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2024-06-21

No results posted yet for this study

Summary

After developing and pilot testing the training program, including the CogBals software, a 3-arm, single-blinded, randomized controlled trial is used to recruit 84 participants and then randomly allocated to the cognitive and balance dual task training group (COG\&BAL), the balance training group (BAL), and the treatment as usual group. The first two training groups (COG\&BAL, BAL) receive training for 60 minutes in a group format, 2 times weekly, for 12 weeks. All participants will be assessed at baseline and posttest. The primary outcome is balance function and secondary outcomes are cognitive functions and the muscular endurance of lower extremities.

Conditions

  • Schizophrenia
  • Cognition
  • Balance
  • Dual Task
  • Mental Illness
  • Psychiatric Disorder
  • Fall Prevention

Interventions

BEHAVIORAL

cognitive and balance dual task training

a cognitive and balance dual task training program involving the Internet of Thing technique software - Cognitive and Balance training Simultaneously software

BEHAVIORAL

balance training

Includes static balance, dynamic balance and strength training

Sponsors & Collaborators

  • Kaohsiung Medical University

    collaborator OTHER

  • Ministry of Science and Technology, Taiwan

    collaborator OTHER_GOV

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-10
Primary Completion
2023-09-15
Completion
2023-09-15

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05341804 on ClinicalTrials.gov